Onsdag 21 Januari | 16:53:26 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-01-12 - Extra Bolagsstämma 2026
2025-08-28 - Kvartalsrapport 2025-Q2
2025-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2025-06-05 - Årsstämma
2025-04-10 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-06-19 - Årsstämma
2024-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2024-04-25 - Bokslutskommuniké 2023
2023-10-04 - Split CRNA 30:1
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-22 - Årsstämma
2023-04-21 - X-dag ordinarie utdelning CRNA 0.00 NOK
2023-03-09 - Extra Bolagsstämma 2023
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-20 - Årsstämma
2022-04-07 - X-dag ordinarie utdelning CRNA 0.00 NOK
2022-02-17 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-03-18 - X-dag ordinarie utdelning CRNA 0.00 NOK
2021-03-17 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-30 - X-dag ordinarie utdelning CRNA 0.00 NOK
2020-04-29 - Årsstämma
2020-03-11 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-09 - Kvartalsrapport 2019-Q1
2019-04-10 - X-dag ordinarie utdelning CRNA 0.00 NOK
2019-04-09 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-03 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning CRNA 0.00 NOK
2018-04-11 - Årsstämma
2018-02-15 - Bokslutskommuniké 2017
2017-11-16 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-04-25 - Kvartalsrapport 2017-Q1
2017-04-05 - Årsstämma
2017-02-16 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-14 - X-dag ordinarie utdelning CRNA 0.00 NOK
2016-04-13 - Årsstämma
2015-06-23 - X-dag ordinarie utdelning CRNA 0.00 NOK
2015-06-22 - Årsstämma

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriBioteknik
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-01-21 15:12:00

Oslo, 21 January 2026: Reference is made to the stock exchange announcements by Circio Holding ASA (the “Company“) on 15 January 2026, regarding the commencement of the subscription period for the rights issue (the “Rights Issue“) and the receipt of subscription rights in the Rights Issue by certain primary insiders and close associates.

Oslo, 21 January 2026: Reference is made to the stock exchange announcements by Circio Holding ASA (the “Company“) on 15 January 2026, regarding the commencement of the subscription period for the rights issue (the “Rights Issue“) and the receipt of subscription rights in the Rights Issue by certain primary insiders and close associates.

Certain primary insiders and close associates have on the dates as stated below, exercised subscription rights and subscribed for shares:

  • Ola Melin, Chief Operation Officer of the Company has on 21 January 2026 exercised 33,161 subscription rights, thus entitling him to be allocated 33,161 offer shares in the Rights Issue. In addition, Ola Melin has subscribed for 116,839 offer shares without subscription rights, thereby subscribing for a total of 150,000 offer shares at the subscription price in the Rights Issue, i.e., NOK 1.00 per offer share, and to be allocated a corresponding number in warrants without additional consideration, subject to allocation by the board of directors and the completion of the Rights Issue.
  • Thomas Birkballe Hansen, Chief Technology Officer of the Company has on 19 January 2026 exercised 32,582 subscription rights, thus entitling him to be allocated 32,582 offer shares in the Rights Issue. In addition, Thomas Birkballe Hansen has subscribed for 167,418 offer shares without subscription rights, thereby subscribing for a total of 200,000 offer shares at the subscription price in the Rights Issue, i.e., NOK 1.00 per offer share, and to be allocated a corresponding number in warrants without additional consideration, subject to allocation by the board of directors and the completion of the Rights Issue.
  • Diane Mary Mellet, Board member of the Company has on 21 January 2026 exercised 60,000 subscription rights, thus entitling her to be allocated 60,000 offer shares in the Rights Issue, at the subscription price in the Rights Issue, i.e., NOK 1.00 per offer share, and to be allocated a corresponding number in warrants without additional consideration, subject to the completion of the Rights Issue.
  • Robert Forbes Burns, Deputy Board member of the Company has on 21 January 2026 exercised 11,542 subscription rights, thus entitling him to be allocated 11,542 offer shares in the Rights Issue, at the subscription price in the Rights Issue, i.e., NOK 1.00 per offer share, and to be allocated a corresponding number in warrants without additional consideration, subject to the completion of the Rights Issue.
  • Damian Marron, Chairman of the Board of the Company has on 21 January 2026 exercised 58,918 subscription rights, thus entitling him to be allocated 58,918 offer shares in the Rights Issue. In addition, Damian Marron has subscribed for 61,082 offer shares without subscription rights, thereby subscribing for a total of 120,000 offer shares at the subscription price in the Rights Issue, i.e., NOK 1.00 per offer share, and to be allocated a corresponding number in warrants without additional consideration, subject to allocation by the board of directors and the completion of the Rights Issue.

Please see the attached notifications of trade for information regarding the subscription rights exercised by primary insiders in the Rights Issue.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.